Vivos Therapeutics, Inc. (CIK: 0001716166) filed an 8-K with the Securities and Exchange Commission (SEC) on October 19, 2026, detailing a significant acquisition involving SOD Sciences, Inc. This filing is important for investors and stakeholders as it outlines changes that could impact the company’s growth and operations.

Background on Vivos Therapeutics

Vivos Therapeutics is a medical technology company based in Littleton, Colorado. It specializes in developing innovative solutions for sleep-related disorders and other health issues. The company is publicly traded on the Nasdaq under the symbol VVOS. The 8-K form is used to report major events that shareholders should know about, including acquisitions, financial performance, and changes in management.

Details from the Filing

The 8-K filing (accession number 0001493152-26-047601) includes several key points:

  • On October 14, 2026, Vivos entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences. This agreement allows Vivos to acquire a minority equity interest in SOD and a 50% co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property.
  • In exchange, Vivos issued 12,000 shares of its Series C Convertible Preferred Stock to SOD.
  • Subsequent amendments to the agreement were made on October 15 and 16, 2026, extending the closing date and correcting a clerical error regarding SOD’s state of incorporation.
  • On the closing date, Vivos completed the acquisition of 3,057,879 shares of SOD, representing at least 11% of SOD's fully diluted capital stock.
  • No cash consideration was involved in the transaction.
  • The Series C Preferred shares issued are convertible into common stock at a price of $0.15 per share, subject to certain conditions.

Vivos also indicated that the Series C Preferred shares rank senior to common stock regarding dividends and liquidation rights.

Impact of the Filing

This acquisition may have several implications for Vivos Therapeutics. By acquiring a co-ownership interest in SOD’s intellectual property, Vivos could enhance its product offerings and market position in the medical technology sector. This move could also attract interest from investors looking for companies with innovative solutions in healthcare.

Additionally, the issuance of preferred stock may impact existing shareholders by diluting their ownership if the preferred shares are converted into common stock. However, the company has indicated that there are limitations on the number of shares that can be converted without shareholder approval.

What's Next?

The filing does not specify what happens next. However, stakeholders will likely be watching for further developments regarding the integration of SOD’s technology into Vivos’ offerings and any future financial reports that may reflect the impact of this acquisition.